Acer India join hands with Dixon Technologies to manufacture 5,00,000 laptops annually in Noida
Acer India join hands with Dixon Technologies to manufacture 5,00,000 laptops annually in Noida

Acer India join hands with Dixon Technologies to manufacture 5,00,000 laptops annually in Noida

Acer to manufacture laptops under the value, mainstream, and education segment category at the Dixon factory which will boost employment generation in the region.

DSIJ Intelligence Article rating: 4.0

This will give a strong impetus to India's manufacturing competitiveness and leverage the production-linked incentive (PLI) by the Government of India. Acer will bring in the global know-how and processes to manufacture high-tech electronic products in the laptops category which will be implemented through Dixon’s facilities.

TVS inks MoU with Government of Tamil Nadu to invest Rs 1200 crore in EV space
TVS inks MoU with Government of Tamil Nadu to invest Rs 1200 crore in EV space

TVS inks MoU with Government of Tamil Nadu to invest Rs 1200 crore in EV space

The investment will be mainly for the design, development and manufacturing of new products and capacity expansion in the EV space.

DSIJ Intelligence Article rating: 3.7

TVS Motor Company, one of the largest manufacturers of two-wheelers and three-wheelers in the world, today announced that they have signed a Memorandum of Understanding (MOU) with the Government of Tamil Nadu for investment in Future Technologies and Electric Vehicle.

Laurus Labs acquires a small stake in cell and gene therapy company - ImmunoACT
Laurus Labs acquires a small stake in cell and gene therapy company - ImmunoACT

Laurus Labs acquires a small stake in cell and gene therapy company - ImmunoACT

In India, CAR-T therapy is not available and this collaboration will help them in bringing this novel technology to Indian patients at very affordable pricing.

DSIJ Intelligence Article rating: 3.7

Laurus Labs has signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire a 26.62 per cent stake (fully diluted basis) for a cash consideration of approximately Rs 46 crore, subject to the fulfilment of certain conditions. 

Biocon Biologics and Viatris to offer insulin glargine injection at a discounted price
Biocon Biologics and Viatris to offer insulin glargine injection at a discounted price

Biocon Biologics and Viatris to offer insulin glargine injection at a discounted price

Members can save up to 80 per cent off the cash price of comparable long-acting insulins purchased at Walgreens

DSIJ Intelligence Article rating: 5.0

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, and Viatris Inc confirm that Insulin Glargine injection will be offered through the Walgreens Prescription Savings Club, saving members up to 80 per cent off the cash price of comparable long-acting insulins purchased at Walgreens. 

Zydus Cadila gets approval to market unique cancer drug in the US
Zydus Cadila gets approval to market unique cancer drug in the US

Zydus Cadila gets approval to market unique cancer drug in the US

Zydus is the 'first approved applicant' for Nelarabine Injection which had annual sales of approximately US$ 34.5 million in the United States.

DSIJ Intelligence Article rating: 5.0

Zydus Cadila has received final approval from the USFDA to market Nelarabine Injection 250MG/50ML in the United States. Zydus Pharmaceuticals USA Inc (Zydus) was granted a Competitive Generic Therapy (CGT) designation for Nelarabine Injection, Single-Dose Vial. 

Phoenix Mills and CPP Investments collaborate to develop a project in Mumbai
Phoenix Mills and CPP Investments collaborate to develop a project in Mumbai

Phoenix Mills and CPP Investments collaborate to develop a project in Mumbai

The office-led mixed-use asset will complement the prevailing retail development at Phoenix Palladium and therefore The St. Regis Mumbai hotel.

DSIJ Intelligence Article rating: 5.0

The Phoenix Mills Limited (PML) and Canada Pension Plan Investment Board (CPP Investments) today announced a new joint venture to develop an office-led mixed-use asset in Lower Parel, Mumbai. The asset forms bigger mixed-use development at Phoenix Palladium, Mumbai

TCS to drive IT Agile Transformation and DevSecOps Services for Zebra Technologies
TCS to drive IT Agile Transformation and DevSecOps Services for Zebra Technologies

TCS to drive IT Agile Transformation and DevSecOps Services for Zebra Technologies

TCS will play a key role in the end-to-end global agile transformation of Zebra Technology’s IT that supports its systems used by 8,800 employees in 45 countries

DSIJ Intelligence Article rating: 5.0

Tata Consultancy Services (TCS), a leading global IT giant that provides services, consulting, and business solutions for organizations, announced a strategic transformation engagement with Zebra Technologies Corporation. 

Nucleus Software Q2 results disappoint with poor revenue and net profit growth
Nucleus Software Q2 results disappoint with poor revenue and net profit growth

Nucleus Software Q2 results disappoint with poor revenue and net profit growth

Nucleus Software powers the operations of more than 200 Financial Institutions in over 50 countries.

DSIJ Intelligence Article rating: 5.0

Q2 result: Revenue delined 18.6 per cent on YoY basis, Net profit declined 248 per cent on YoY bais, company had weak margins in Q2 quarter due to increase in mployee benefit expenses.

Earnings report: Britannia Q2 results miss street estimates
Earnings report: Britannia Q2 results miss street estimates

Earnings report: Britannia Q2 results miss street estimates

On the cost front, the global economy continued to witness supply led constraints across various input materials fueling inflation

DSIJ Intelligence Article rating: 4.0

Britannia reported a 23 per cent year-on-year decline in its consolidated net profit to Rs 384.22 crore for the quarter ended September, which was below analysts’ expectations. 

Cadila Healthcare to supply one crore doses of ZyCoV-D to Government of India
Cadila Healthcare to supply one crore doses of ZyCoV-D to Government of India

Cadila Healthcare to supply one crore doses of ZyCoV-D to Government of India

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus.

DSIJ Intelligence Article rating: 3.0

Zydus Cadila has received an order to supply one crore doses of ZyCoV-D, the world’s first Plasmid DNA Vaccine, to the Government of India at Rs 265 per dose and the needle-free applicator being offered at Rs 93 per dose

RSS
1234567

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR